Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

ESMO Guidelines Committee

doi:10.1016/j.annonc.2021.06.015

Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^☆

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

113 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1087-1100
Nombre de pages	14
journal	Annals of Oncology
Volume	32
Numéro de publication	9
Les DOIs	https://doi.org/10.1016/j.annonc.2021.06.015
état	Publié - 1 sept. 2021

Accès au document

10.1016/j.annonc.2021.06.015

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{e9d51636419f43bb9c835fd18b662373,

title = "Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆",

keywords = "anal cancer, clinical practice guidelines, diagnosis, follow-up, treatment",

author = "{ESMO Guidelines Committee} and S. Rao and Guren, {M. G.} and K. Khan and G. Brown and Renehan, {A. G.} and Steigen, {S. E.} and E. Deutsch and E. Martinelli and D. Arnold",

note = "Funding Information: This Clinical Practice Guideline was reviewed by Arndt Vogel on behalf of the ESMO Guidelines Steering Committee. Manuscript editing support was provided by Angela Corstorphine (Kstorfin Medical Communications Ltd), Louise Green and Catherine Evans (ESMO Guidelines Staff). This support was funded by ESMO. Funding Information: This Clinical Practice Guideline was reviewed by Arndt Vogel on behalf of the ESMO Guidelines Steering Committee. Manuscript editing support was provided by Angela Corstorphine (Kstorfin Medical Communications Ltd), Louise Green and Catherine Evans (ESMO Guidelines Staff). This support was funded by ESMO. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. DA reports receipt of honoraria for advisory boards, educational activities and/or presentations from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Roche, Sanofi, Servier, Sirtex, Terumo, Art Tempi, PriME Oncology and TRM Oncology; travel support from AstraZeneca, Bristol-Myers Squibb, Roche and Sanofi; research funding to institute from AstraZeneca, Incyte, Merck Sharp & Dohme, Roche and Sanofi; and non-renumerated activities (advisory role and/or principal investigator function) for Mologen and Oncolytics. ED reports grants and personal fees from Roche Genentech and Merck Serono and grants from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb and Merck Sharp & Dohme. EM has served as a speaker for Merck Serono, Servier and Amgen, and as an advisor for Pierre-Fabre, Incyte, Bayer, AstraZeneca, Roche, Sanofi and ESMO. MGG has received institutional research funding from Bristol-Myers Squibb, Incyte and Merck Sharp & Dohme. SR reports receipt of honoraria for advisory boards from Bayer, Roche, Servier, Merck Serono and received travel support from Incyte, Bayer and Servier. KK, GB, AGR and SES have declared no conflicts of interest.",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2021.06.015",

language = "English",

volume = "32",

pages = "1087--1100",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "9",

}

TY - JOUR

T1 - Anal cancer

T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

AU - ESMO Guidelines Committee

AU - Rao, S.

AU - Guren, M. G.

AU - Khan, K.

AU - Brown, G.

AU - Renehan, A. G.

AU - Steigen, S. E.

AU - Deutsch, E.

AU - Martinelli, E.

AU - Arnold, D.

N1 - Funding Information: This Clinical Practice Guideline was reviewed by Arndt Vogel on behalf of the ESMO Guidelines Steering Committee. Manuscript editing support was provided by Angela Corstorphine (Kstorfin Medical Communications Ltd), Louise Green and Catherine Evans (ESMO Guidelines Staff). This support was funded by ESMO. Funding Information: This Clinical Practice Guideline was reviewed by Arndt Vogel on behalf of the ESMO Guidelines Steering Committee. Manuscript editing support was provided by Angela Corstorphine (Kstorfin Medical Communications Ltd), Louise Green and Catherine Evans (ESMO Guidelines Staff). This support was funded by ESMO. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. DA reports receipt of honoraria for advisory boards, educational activities and/or presentations from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boston Scientific, Eli Lilly, Merck Serono, Merck Sharp & Dohme, Roche, Sanofi, Servier, Sirtex, Terumo, Art Tempi, PriME Oncology and TRM Oncology; travel support from AstraZeneca, Bristol-Myers Squibb, Roche and Sanofi; research funding to institute from AstraZeneca, Incyte, Merck Sharp & Dohme, Roche and Sanofi; and non-renumerated activities (advisory role and/or principal investigator function) for Mologen and Oncolytics. ED reports grants and personal fees from Roche Genentech and Merck Serono and grants from Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb and Merck Sharp & Dohme. EM has served as a speaker for Merck Serono, Servier and Amgen, and as an advisor for Pierre-Fabre, Incyte, Bayer, AstraZeneca, Roche, Sanofi and ESMO. MGG has received institutional research funding from Bristol-Myers Squibb, Incyte and Merck Sharp & Dohme. SR reports receipt of honoraria for advisory boards from Bayer, Roche, Servier, Merck Serono and received travel support from Incyte, Bayer and Servier. KK, GB, AGR and SES have declared no conflicts of interest.

PY - 2021/9/1

Y1 - 2021/9/1

KW - anal cancer

KW - clinical practice guidelines

KW - diagnosis

KW - follow-up

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85111553802&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.06.015

DO - 10.1016/j.annonc.2021.06.015

M3 - Article

C2 - 34175386

AN - SCOPUS:85111553802

SN - 0923-7534

VL - 32

SP - 1087

EP - 1100

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -